A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT04973605
Trial Phases:	Phase I Phase II	Protocol IDs:	BGB-11417-105 (primary) NCI-2022-07236 2021-003614-39 U1111-1277-5444
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	BeOne Medicines
NCI Full Details:	http://clinicaltrials.gov/show/NCT04973605

Summary

The purpose of this study is to assess the safety, tolerability, and efficacy of
sonrotoclax as monotherapy and in various combinations in patients with
relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).

The study investigates sonrotoclax alone and in combination with dexamethasone and other
agents, including carfilzomib, daratumumab, and pomalidomide.

Objectives

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some
of our older studies were sponsored under the name BeiGene, you may see both names used
for this study on this website.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.